Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib.
Upadacitinib (UPA), like other Janus kinase inhibitors (JAKis), has regulatory safety warnings related to cardiovascular risk (CVR) and malignancy. This study aims to identify clinical and demographic factors associated with UPA treatment persistence and to assess the impact of…